SLC5A2 and atrial fibrillation: The mechanism behind the beneficial impacts of SGLT2 inhibitors on MACE risk observed in the current meta-analysis is not clear but possibly due to the prevention of atrial fibrillation flutter (AFL) and atrial fibrillation (AF) [30].